Abstract 17P
Background
Early CD8+ T cell responses to PD-1 blockade are well-characterised. However, an understanding of the long-term clonal and transcriptomic signatures of complete response (CR) to Immune Checkpoint Blockade (ICB) is currently lacking. We aimed to identify and describe CD8+ T cell clonal and transcriptomic changes post complete response to PD-1 blockade in metastatic melanoma (MM).
Methods
We performed single-cell RNA sequencing (scRNAseq) of both the T cell receptor (TCR) and transcriptomes of PBMCs and sorted peripheral CD8+ T cells in patients with MM with a complete response to PD-1 blockade (n=10), patients with progressive disease (PD, n=6) and healthy donors (HD, n=2). Blood was sampled at multiple time points, including a median of 3.2 years following cessation of PD-1 blockade for CR.
Results
Following a CR and cessation of ICB, there is increased abundance of a subtype of CD8+ T cell characterised by high expression of NK-associated genes, termed a killer-like subset. Using the top 25 genes upregulated by this subset to generate a ‘Killer Score’, we show that patients with CR to anti-PD-1 demonstrate a broad increase in killer gene expression over time absent in those with PD and HDs. By tracking key clones through TCR usage, we identify those which are stable/expanding from pre-treatment to post treatment, occupy >0.5% of the repertoire and are persistent post-cessation of ICB, terming these large expanding persistent clones. These clones have a predominantly cytotoxic, effector, gene expression profile and display surface markers consistent with a recently-described ‘Long-lived Effector Cell’ subtype.
Conclusions
CR to PD-1 blockade is associated with persistence of highly-cytotoxic effector CD8+ T cells that circulate years after cessation of treatment. Whilst similar subsets have been implicated with chronic viral infection, these observations are novel in the cancer setting and have important implications for mechanisms of durable disease control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Wellcome Trust, Cancer Research UK, National Institute for Health Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09